DMRA Company Profile and Key Details

Damora Therapeutics, Inc. (NASDAQ:DMRA) closed at $28.26 USD, gaining $1.42 (5.29%) from the previous close of $26.84. The stock is currently mid-range between its 52-week high and low $2.53 and $38.33. With a market capitalization of about $1.74 billion, Damora Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 575.91 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Damora Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer A. Jarrett, the company employs approximately 7 people and listed since October 29, 2020. Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Average 10-day trading volume of 437.00 thousand shares is below the 3-month average of 571.49 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $35.00. The high target offers 86.29% upside. The low target suggests 30.4% downside. The mean target is $41.43. This offers 54.36% upside. Damora Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by -5.79%. The prior quarter beat by -5.68%. Over the last six quarters, Apple has recorded several small beats. These include 2216.35% in March 18, 2026.

Damora Therapeutics, Inc. has 61.74 million shares outstanding. The public float is 41.40 million shares, elevated short interest at 9.25% of float. This equals 4.89 million shares. The short ratio is 9.72 days. Institutional investors hold 101.88% of the float. Insiders own 7.62%. Over the past six months, insider transactions show net selling. They sold 245.00 shares across 1 transactions.

Our AI price prediction model suggests that Damora Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.87%, with price expected at $24.46 by September 24, 2026, within a range of $23.54 to $25.40 3-Month Outlook: Projected rise of 72.58%, reaching $46.32 by December 09, 2026, with a range of $46.00 to $46.61. 1-Year Outlook: Projected gain of 6.37%, with price at $28.55 by September 10, 2027, within a range of $28.31 to $28.86.

Valuation shows Damora Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.22. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $41.43, suggesting 54.36% upside. Our AI forecast model points to short-term weakness (-8.87% over two weeks), a medium-term rise (72.58% over three months), and a longer-term gain (6.37% over one year), with expected trading ranges indicating moderate volatility.

Damora Therapeutics, Inc. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.2 trading at moderately above to book value. The P/FCF stands at -39.67, also below market averages.